Denali Therapeutics (DNLI) vs Arcus Biosciences (RCUS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Arcus Biosciences (RCUS) has outperformed Denali Therapeutics (DNLI) over the past year, gaining 58.3% versus a gain of 19.3%. Over five years, RCUS leads with a -28.7% price change compared with -59.0% for DNLI. Arcus Biosciences is the larger company by market cap ($3.00 billion vs $2.98 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNLI | RCUS |
|---|---|---|
| Share price | $18.67 | $23.83 |
| Market cap | $2.98B | $3.00B |
| 1-day change | -2.56% | -2.81% |
| YTD return | +13.08% | 0.00% |
| 1-year return | +19.30% | +58.34% |
| 5-year return | -59.02% | -28.70% |
| EPS (TTM) | $-2.84 | $-3.91 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $247.00M |
| Revenue growth (YoY) | — | -4.26% |
| Net income (latest FY) | $-512.54M | $-353.00M |
| Operating margin | — | -156.28% |
| Net margin | — | -142.91% |
| 52-week high | $27.30 | $31.74 |
| 52-week low | $13.75 | $14.26 |
| Distance from 52-week high | -31.61% | -24.91% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +93.14% | +67.48% |
| Average volume | 1.61M | 1.32M |
| Shares outstanding | 159.85M | 125.77M |
| Employees | 503 | 601 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RCUS has outperformed DNLI by 39.0 percentage points over the past year.
About Denali Therapeutics
DNLI stock →Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 503 employees
About Arcus Biosciences
RCUS stock →Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody.
Health Care · Biotechnology: Pharmaceutical Preparations · 601 employees
DNLI vs RCUS FAQ
Which is bigger, Denali Therapeutics or Arcus Biosciences?
Arcus Biosciences (RCUS) is larger, with a market capitalization of $3.00B compared with $2.98B for Denali Therapeutics (DNLI).
Which stock has performed better over the past year, DNLI or RCUS?
RCUS returned +58.34% over the past 12 months, compared with +19.30% for DNLI (price return, excluding dividends). Past performance does not predict future results.
Are Denali Therapeutics and Arcus Biosciences in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Denali Therapeutics and Biotechnology: Pharmaceutical Preparations for Arcus Biosciences.